Actavis To Pay $66 Billion For Allergan, Establishing A “Growth Pharma”
This article was originally published in The Pink Sheet Daily
Executive Summary
The generics giant, after buying Forest, is further diversifying into specialty pharma with the acquisition of Botox marketer Allergan for $219 per share. Valeant said it doesn’t plan to counter.
You may also be interested in...
Actavis’ Big Bet On Diversified Hybrid Model Reflects Industry Trends
Actavis’ proposal to buy Forest Labs for $25 billion in stock and cash was driven by consolidating customers and fierce competition in traditional Western markets. Different pressures, namely the tough-to-manage patent cliff, as well as leadership succession issues and investor unrest, drove Forest into the arms of a suitor.
IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
Zafgen Drops Beloranib, But Its New Focus Raises Doubts
The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.